All In Biotech

Drug Trial Radar · NCT04603833

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

A Phase II Clinical Study of SHR3680 Combined With Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone

Last checked: Nov 19, 2026Latest source record: Feb 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 2, 2020

Primary completion

Oct 1, 2022

Study completion Dec 31, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.

Conditions

  • Prostate Cancer Metastatic

Interventions

  • SHR3680+DocetaxelDrug

    Participants will receive SHR3680 combined with Docetaxel

  • SHR3680Drug

    Participants will receive SHR3680

  • DocetaxelDrug

    Participants will receive Docetaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to prostate specific antigen (PSA) progressionTime frame: [Time Frame: Approximately 24 months]
  2. Adverse Event(AE)Time frame: [Time Frame: Approximately 24 months]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.